UK Updates Post-Market Surveillance Requirements for Medical Devices
The Medicines and Healthcare products Regulatory Agency (MHRA) has released updated guidance on post-market surveillance (PMS) requirements for medical devices in Great Britain. The document, titled "The Medical Devices Post-Market Surveillance Requirements (Amendment) Great Britain Regulations 2024: Guidance on Implementation," provides clarification and details on fulfilling the regulatory obligations for manufacturers.
MedNet EC-REP
Author

The updated guidance likely addresses changes and amendments to existing regulations, ensuring a more robust and responsive PMS system. Medical device manufacturers should carefully review the document to understand the specific requirements and ensure compliance. Key areas likely covered in the guidance include:
- Reporting requirements: Updated timelines or procedures for reporting adverse events or incidents related to medical devices.
- Data collection and analysis: Expectations for collecting and analyzing post-market data to identify potential safety or performance issues.
- Corrective and preventive actions (CAPA): Guidelines for implementing CAPA plans to address identified issues and prevent recurrence.
- Periodic safety update reports (PSURs): Requirements for preparing and submitting PSURs to demonstrate ongoing monitoring of device safety and performance.
Manufacturers placing medical devices on the Great Britain market should prioritize a thorough review of this guidance to ensure their PMS systems align with the latest regulatory expectations. Non-compliance can lead to penalties and market access restrictions.
If any individual devices are placed on the GB market after 16 June 2025, all applicable requirements must be fulfilled.
For more detailed information, refer to the official MHRA guidance document available on the UK government website.
Related Articles

Well-Established Technologies Under the MDR: EU Commission Expands Exemption List
The EU Commission has expanded the WET list under the MDR, easing requirements for certain class II and class III devices.

MHRA Device Registration: New Clarification on "Placing on the Market" and "Putting into Service" (Update 20 July 2026)
MHRA clarifies medical device registration: 20 July 2026 update explains "placing on the market" vs. "putting into service" in GB.

EC REP Becomes EU REP: What the New Authorised Representative Symbol Means for Medical Device Manufacturers
In short: On 17 June 2026, the European Commission published the reference of EN ISO 15223-1:2021/A1:2025 in the Official Journal of the European Union (OJEU) for both the MDR and the IVDR. This amendment replaces the long-standing "EC REP" symbol with "EU REP" for the authorised representative in the European Union. The change is purely editorial, and you have a five-year transition period - until 17 June 2031 - during which both symbols remain valid.
Stay Updated
Get the latest regulatory updates and industry insights delivered to your inbox.
Subscribe to Updates